Therapies for pulmonary arterial hypertension: Where are we today, where do we go tomorrow?

European Respiratory Review

Volumn 22, Issue 129, 2013, Pages 217-226

  Seferian, Andrei ^a,b,c   Simonneau, Gérald ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; AMBRISENTAN; BERAPROST; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; FASUDIL; GUANOSINE PHOSPHATE; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; IMATINIB; MACITENTAN; NITRIC OXIDE; PHOSPHODIESTERASE V; PLACEBO; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RIOCIGUAT; SELEXIPAG; SILDENAFIL; SITAXSENTAN; TADALAFIL; TERGURIDE; TREPROSTINIL; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACUTE LIVER FAILURE; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGENETICS; FLUSHING; GENE THERAPY; HUMAN; INFUSION RELATED REACTION; JAW PAIN; LIVER INJURY; MYALGIA; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SUBDURAL HEMATOMA; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84883331015     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00001713     Document Type: Review

References (106)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54
3. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000; 102: 2781-2791.
4. Sparacino-Watkins CE, Lai YC, Gladwin MT. Nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics. Circulation 2012; 125: 2824-2826.
5. Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci 2012; 91: 517-521.
6. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184-1187.
7. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
8. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
9. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
10. Fadel E, Mercier O, Mussot S, et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg 2010; 38: 277-284.
11. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
12. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
13. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
14. Vane J, Corin RE. Prostacyclin: a vascular mediator. Eur J Vasc Endovasc Surg 2003; 26: 571-578.
15. Wharton J, Davie N, Upton PD, et al. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000; 102: 3130-3136.
16. Li RC, Cindrova-Davies T, Skepper JN, et al. Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ Res 2004; 94: 759-767.
17. Kothapalli D, Stewart SA, Smyth EM, et al. Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein-and pocket protein-dependent cyclin a gene expression. Mol Pharm 2003; 64: 249-258.
18. Montani D, O'Callaghan DS, Jais X, et al. Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. Eur Respir Rev 2009; 18: 272-290.
19. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-491.
20. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415.
21. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
22. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
23. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovascu Pharmacol 2004; 44: 209-214.
24. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1586-1589.
25. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922.
26. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142: 1383-1390.
27. PR Newswire. FREEDOM-M trial of oral treprostinil in pulmonary arterial hypertension meets primary endpoint. http://www.prnewswire.com/news-releases/freedom-m-trial-of-oral-treprostinil-in-pulmonary-arterial-hypertensionmeets-primary-endpoint-123212773.html Date last accessed: January 2013. Date last updated: June 6, 2011.
28. Olschewski H, Simonneau G, Galié N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
29. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. European heart journal 2005; 26: 1895-1902.
30. Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009; 34: 132-137.
31. Galié N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
32. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
33. Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. Journal Pharmacol Exp Ther 2007; 322: 1181-1188.
34. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40: 874-880.
35. Raja SG, Dreyfus GD. Current status of bosentan for treatment of pulmonary hypertension. Ann Card Anaesth 2008; 11: 6-14.
36. Raja SG. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Cardiovasc Ther 2010; 28: e65-e71.
37. Pollock DM. Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension 2005; 45: 477-480.
38. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91: 1367-1373.
39. Rubin LJ, Dufton C, Gerber MJ. Ambrisentan for pulmonary arterial hypertension. Future Cardiol 2005; 1: 425-432.
40. Opitz CF, Ewert R. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Eur J Clin Invest 2006; 36: Suppl. 3, 1-9.
41. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
42. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
43. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
44. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 1212-1217.
45. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502-508.
46. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122-129.
47. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
48. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: 1971-1981.
49. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012; 30: 93-99.
50. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327: 736-745.
51. Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PloS One 2012; 7: e47662.
52. Sidharta PN, van Giersbergen PL, Halabi A, et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011; 67: 977-984.
53. Actelion. Macitentan. http://www1.actelion.com/sites/en/scientists/development-pipeline/phase-3/macitentan.page Date last accessed January 2013. Date Last updated: January 2013.
54. Rubin L, Pulido T, Channick R, et al. Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): results from the SERAPHIN trial. CHEST 2012; 142: 1026A.
55. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.
56. Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009; 34: 770-771.
57. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
58. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
59. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
60. O'Callaghan DS, Savale L, Yaïci A, et al. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2011; 12: 1585-1596.
61. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev 2009; 18: 35-41.
62. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011; 140: 1274-1283.
63. Ghofrani H, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1). CHEST 2012; 142: 1027A.
64. Wayne N.J. Bayer's investigational riociguat meets primary endpoint in phase III study in patients with pulmonary arterial huypertension (PAH). www.prnewswire.com/news-releases/bayers-investigational-riociguat-meets-primaryendpoint-in-phase-iii-study-in-patients-with-pulmonary-arterial-hypertension-pah-175181281.html Date last accessed: January 2013. Date last updated: October 22, 2012.
65. Bayer's investigational riociguat meets primary endpoint in phase III study of patients with chronic thromboembolic pulmonary hypertension (CTEPH). www.prnewswire.com/news-releases/bayers-investigational-riociguat-meetsprimary-endpoint-in-phase-iii-study-of-patients-with-chronic-thromboembolic-pulmonary-hypertension-cteph-175479511.html Date last accessed: January 2013. Date last updated: October 23, 2012.
66. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008; 118: 1195-1201.
67. Sitbon O, Humbert M, Jaïis X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
68. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84.
69. Gaine S. Pulmonary hypertension. JAMA 2000; 284: 3160-3168.
70. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-559.
71. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005; 115: 2691-2694.
72. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1171.
73. Hoeper M, Barst RJ, Galié N, et al. Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES). Eur Respir J, 2011: Suppl. 55, A413.
74. Abe K, Toba M, Alzoubi A, et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mole Biol 2011; 45: 804-808.
75. Zakrzewski D, Seferynska I, Warzocha K, et al. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. Int J Hematol 2012; 96: 132-135.
76. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009; 48: 964-970.
77. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344.
78. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
79. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
80. Dempsie Y, MacLean MR. Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol 2008; 155: 455-462.
81. Dumitrascu R, Kulcke C, Königshoff M, et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 2011; 37: 1104-1118.
82. Ghofrani HA, Al-Hiti H, Vonk-Noordegraaf H, et al. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase IIa study. Am J Respir Crit Care Med 2012; 185: A2496.
83. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339-1346.
84. Maruno K, Absood A, Said SI. VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am J Physiol 1995; 268: L1047-L1051.
85. Cox CP, Linden J, Said SI. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 1984; 5: 325-328.
86. Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008; 32: 1289-1294.
87. Galie N, A. Boonstra, Ewert R, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH). Am. J. Respir. Crit. Care Med 2010; 181: A2516.
88. Nagaoka T, Fagan KA, Gebb SA, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005; 171: 494-499.
89. Homma N, Nagaoka T, Karoor V, et al. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol 2008; 295: L71-L78.
90. Fujita H, Fukumoto Y, Saji K, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010; 25: 144-149.
91. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91: 391-392.
92. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010; 181: 1106-1113.
93. Kawut SM, Bagiella E, Lederer DJ, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011; 123: 2985-2993.
94. Zhao L, Brown LA, Owji AA, et al. Adrenomedullin activity in chronically hypoxic rat lungs. Am J Physiol 1996; 271: Suppl. 2, H622-H629.
95. Nagaya N, Kyotani S, Uematsu M, et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004; 109: 351-356.
96. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447: 433-440.
97. Adcock IM, Tsaprouni L, Bhavsar P, et al. Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007; 19: 694-700.
98. Perez-Vizcaino F, Cogolludo A, Moreno L. Reactive oxygen species signaling in pulmonary vascular smooth muscle. Respir Physiol Neurobiol 2010; 174: 212-120.
99. Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res 2006; 71: 216-225.
100. Fike CD, Slaughter JC, Kaplowitz MR, et al. Reactive oxygen species from NADPH oxidase contribute to altered pulmonary vascular responses in piglets with chronic hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295: L881-L888.
101. International PPHC, Lane KB, Machado RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-b receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-84.
102. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105: 1672-1678.
103. Reynolds AM, Holmes MD, Danilov SM, et al. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J 2012; 39: 329-343.
104. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996; 9: 356-363.
105. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114: 1482-1489.
106. Bendayan D, Hod M, Oron G, et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstec Gynecol 2005; 106: 1206-1210.